- Joined
- Oct 7, 2005
- Messages
- 55
- Reaction score
- 0
UCSF: This was a program I was dying to fall in love with! But . . . I left feeling this program was still very much in transition. Dr. Roach, the interim chair, will likely become the new chair although this has not been made official at the time of my visit. UCSF boasts perennial high boards scores and it is easy to see why. The residents were some of the coolest and smartest I have ever met. The radiobio and radiophysics classes appeared to be well received as well. In the past, the department has had some criticisms regarding didactics and morning conferences. Morning conferences appeared to be improving and becoming more structured. However, faculty attendance at these conferences was still low, with only site-specific attending for the topic being discussed present. The residents appeared to do a lot of self-teaching and learning from each others so one probably has to be quite independent to thrive here. They also appeared to have a decent amount of free time to explore all that San Francisco and its surrounding locales have to offer. Clinics are divided between Mount Zion and the Parnassus campus. There is a shuttle that runs in between the two. Someone mentioned at the interview that Kaiser is starting its own radiation oncology program which could encroach on the patient base at UCSF. Not sure how exactly. UCSF has recently increased its protected research time from 6 to 10 months so its now on par with the other Bay Area programStanford. Many of the applicants I met during the interview have done an away rotation here (not sure what to make of thisjust an observation). UCSF has incredible research opportunities. A quarter of the faculty within the rad onc department have significant protected research time which is impressive. However, no one in the program is currently pursuing the Holman Pathway or a serious commitment to bench research. Perhaps that will change with the new incoming class?
Stanford: Another very high quality program . . . the PD at Stanford, Dr. Donaldson, is rather experienced and very hands-on in terms of residents training. Some senior residents have remarked that the teaching has improved tremendously in recent years after the implementation of a set of conferences and core lecture topics. Residents dont have to present cases at conferences here. They simply go and learn. Residents here cover all patients seen in the department and attend multidisciplinary tumor boards. Despite that, they appear happy and have adequate amount of free time outside work. Stanfords strength complements that of UCSF in terms of disease sites. Stanford is a leader in lymphoma while UCSF is well-known in CNS and GI. What I believe that truly sets the program apart from many others is its strength in biological research. They have a world-class radiobiology department. Many members have R01s. Hypoxia is an overriding theme here. The department seems to favor MD/PhDs since the majority of the residents have dual degrees. Many are also older and have families. The department supports 10 months of protected research which can be conducted in any of the fine laboratories around campus, with PD approval. Even though Stanford supports the Holman Pathway, currently there is only 1 Holman resident. There is an alternative where the department will fund for an 1 year of protected research (on top of the 10 months) if one were willing extend his training (similar to the Wisconsin).
MSKCC: The faculty and residents here are extremely forthcoming. They made no secret in that the clinical responsibilities are heavywe learn by doingand that the department is unlikely to support the Holman pathway anytime soon. This is somewhat unfortunate since the track record of previous Holman residents from here have been overwhelmingly successful. Plus there is so much world-class opportunities around MSKCC with Cornell and Rockefeller nearby. The department is currently searching for a new chair. Perhaps with the new chair, the program may re-examine its position on resident research. Currently, residents are encouraged to conduct several clinical outcome projects throughout residency. They appear very happy overall, despite the heavy clinical load. I have no doubt one will receive excellent training here. MSKCC also offers heavily subsidized apartments (some with gorgeous views) in the heart of Manhattan. Faculty bios read like a Whos Who in Rad Onc. Faculty presents frequently at ASTRO. Many of the applicants I met appeared to have done an away rotation here or otherwise have ties to New York somehow.
Stanford: Another very high quality program . . . the PD at Stanford, Dr. Donaldson, is rather experienced and very hands-on in terms of residents training. Some senior residents have remarked that the teaching has improved tremendously in recent years after the implementation of a set of conferences and core lecture topics. Residents dont have to present cases at conferences here. They simply go and learn. Residents here cover all patients seen in the department and attend multidisciplinary tumor boards. Despite that, they appear happy and have adequate amount of free time outside work. Stanfords strength complements that of UCSF in terms of disease sites. Stanford is a leader in lymphoma while UCSF is well-known in CNS and GI. What I believe that truly sets the program apart from many others is its strength in biological research. They have a world-class radiobiology department. Many members have R01s. Hypoxia is an overriding theme here. The department seems to favor MD/PhDs since the majority of the residents have dual degrees. Many are also older and have families. The department supports 10 months of protected research which can be conducted in any of the fine laboratories around campus, with PD approval. Even though Stanford supports the Holman Pathway, currently there is only 1 Holman resident. There is an alternative where the department will fund for an 1 year of protected research (on top of the 10 months) if one were willing extend his training (similar to the Wisconsin).
MSKCC: The faculty and residents here are extremely forthcoming. They made no secret in that the clinical responsibilities are heavywe learn by doingand that the department is unlikely to support the Holman pathway anytime soon. This is somewhat unfortunate since the track record of previous Holman residents from here have been overwhelmingly successful. Plus there is so much world-class opportunities around MSKCC with Cornell and Rockefeller nearby. The department is currently searching for a new chair. Perhaps with the new chair, the program may re-examine its position on resident research. Currently, residents are encouraged to conduct several clinical outcome projects throughout residency. They appear very happy overall, despite the heavy clinical load. I have no doubt one will receive excellent training here. MSKCC also offers heavily subsidized apartments (some with gorgeous views) in the heart of Manhattan. Faculty bios read like a Whos Who in Rad Onc. Faculty presents frequently at ASTRO. Many of the applicants I met appeared to have done an away rotation here or otherwise have ties to New York somehow.